Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 3, 2003, Pages 428-434

  Becker, Martin J ^a   de Marie, Siem ^a   Fens, Marcel H A M ^a   Verbrugh, Henri A ^a   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aspergillus; Chemokines; Chitin; Galactomannan; Interleukins

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CHEMOKINE; CHITIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTOKINE; GALACTOMANNAN; GAMMA INTERFERON; GENTAMICIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYMYXIN B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL SUPERINFECTION; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INFLAMMATION; LUNG ASPERGILLOSIS; LUNG BIOPSY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; QUANTITATIVE ANALYSIS; RAT;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHITIN; COLONY COUNT, MICROBIAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; KINETICS; LUNG; MANNANS; NEUTROPENIA; RATS; SURVIVAL ANALYSIS;

EID: 0141629325     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg367     Document Type: Article

References (52)

1. Groll, A. H., Shah, P. M., Mentzel, C. et al. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Journal of Infection 33, 23-32.
2. Denning, D. W. (1998). Invasive aspergillosis. Clinical Infectious Diseases 26, 781-803; quiz 804-5.
3. Gerson, S. L., Talbot, G. H., Hurwitz, S. et al. (1984). Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Annals of Internal Medicine 100, 345-51.
4. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23; 608-15.
5. Berenguer, J., Allende, M. C., Lee, J. W. et al. (1995). Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. American Journal of Respiratory Critical Care Medicine 152, 1079-86.
6. Nawada, R., Amitani, R., Tanaka, E. et al. (1996). Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection. Journal of Clinical Microbiology 34, 1433-9.
7. Spreadbury, C. L., Krausz, T., Pervez, S. et al. (1989). Invasive aspergillosis: clinical and pathological features of a new animal model. Journal of Medical and Veterinary Mycology 27, 5-15.
8. Allende, M. C., Lee, J. W., Francis, P. et al. (1994). Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 38, 518-22.
9. Leenders, A. C. & de Marie, S. (1996). The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10, 1570-5.
10. Patterson, T. F., Miniter, P., Ryan, J. L. et al. (1988). Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. Journal of Infectious Diseases 158, 415-22.
11. Cenci, E., Perito, S., Enssle, K. H. et al. (1997). Th1 and Th2 cytokines in mice with invasive aspergillosis. Infection and Immunity 65, 564-70.
12. Cenci, E., Mencacci, A., Del Sero, G. et al. (1999). Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. Journal of Infectious Diseases 180, 1957-68.
13. Del Sero, G., Mencacci, A., Cenci, E. et al. (1999). Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes and Infection 1, 1169-80.
14. Cenci, E., Mencacci, A., Fe d'Ostiani, C. et al. (1998). Cytokine- and T-helper-dependent immunity in murine aspergillosis. Research in Immunology 149, 445-54; discussion 504-5.
15. Duong, M., Ouellet, N., Simard, M. et al. (1998). Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. Journal of Infectious Diseases 178, 1472-82.
16. Mehrad, B., Strieter, R. M. & Standiford, T. J. (1999). Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. Journal of Immunology 162, 1633-40.
17. Mehrad, B., Strieter, R. M., Moore, T. A. et al. (1999). CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. Journal of Immunology 163, 6086-94.
18. Blease, K., Mehrad, B., Lukacs, N. W. et al. (2001). Antifungal and airway remodeling roles for murine monocyte chemoattractant protein-1/CCL2 during pulmonary exposure to Aspergillus fumigatus conidia. Journal of Immunology 166, 1832-42.
19. Leenders, A. C., de Marie, S., ten Kate, M. T. et al. (1996). Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy 38, 215-25.
20. Becker, M. J., de Marie, S., Willemse, D. et al. (2000). Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. Journal of Clinical Microbiology 38, 1434-8.
21. Becker, M. J., Dams, E. T., de Marie, S. et al. (2002). Scintigraphic imaging using 99mTc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. Nuclear Medicine Biology 29, 177-84.
22. Grocott, R. G. (1955). A stain for fungi in tissue sections and smears during Gomori's methenamine-silver nitrate technique. American Journal of Clinical Pathology 25, 975-9.
23. Becker, M. J., De Marie, S., Fens, M. H. et al. (2002). Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. Journal of Antimicrobial Chemotherapy 49, 813-20.
24. Lehmann, P. F. & White, L. O. (1975). Chitin assay used to demonstrate renal localization and cortisone-enhanced growth of Aspergillus fumigatus mycelium in mice. Infection and Immunity 12, 987-92.
25. Lin, S. J., Schranz, J. & Teutsch, S. M. (2001). Aspergillosis case-fatality rate: systematic review of the literature. Clinical Infectious Diseases 32, 358-66.
26. Bowman, J. C., Abruzzo, G. K., Anderson, J. W. et al. (2001). Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrobial Agents and Chemotherapy 45, 3474-81.
27. Lewis, R. E., Prince, R. A., Chi, J. et al. (2002). Itraconazole pre-exposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 46, 3208-14.
28. Francis, P., Lee, J. W., Hoffman, A. et al. (1994). Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. Journal of Infectious Diseases 169, 356-68.
29. Waage, A. & Steinshamn, S. (1993). Cytokine mediators of septic infections in the normal and granulocytopenic host. European Journal of Haematology 50, 243-9.
30. Bone, R. C. (1991). The pathogenesis of sepsis. Annals of Internal Medicine 115, 457-69.
31. Mencacci, A., Cenci, E., Bacci, A. et al. (2000). Cytokines in candidiasis and aspergillosis. Current Pharmaceutical Biotechnology 1, 235-51.
32. Traynor, T. R. & Huffnagle, G. B. (2001). Role of chemokines in fungal infections. Medical Mycology 39, 41-50.
33. Hesse, D. G., Tracey, K. J., Fong, Y. et al. (1988). Cytokine appearance in human endotoxemia and primate bacteremia. Surgery in Gynecology and Obstetrics 166, 147-53.
34. Natanson, C., Eichenholz, P. W., Danner, R. L. et al. (1989). Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. Journal of Experimental Medicine 169, 823-32.
35. Van der Poll, T., Romijn, J. A., Endert, E. et al. (1991). Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. American Journal of Physiology 261, E457-65.
36. Strieter, R. M., Kunkel, S. L. & Bone, R. C. (1993). Role of tumor necrosis factor-alpha in disease states and inflammation. Critical Care Medicine 21, S447-63.
37. Wakabayashi, G., Gelfand, J. A., Jung, W. K. et al. (1991). Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. Journal of Clinical Investigations 87, 1925-35.
38. Lechner, A. J., Ryerse, J. S. & Matuschak, G. M. (1993). Acute lung injury during bacterial or fungal sepsis. Microscopy Research and Technique 26, 444-56.
39. Matuschak, G. M. & Lechner, A. J. (1997). The yeast to hyphal transition following hematogenous candidiasis induces shock and organ injury independent of circulating tumor necrosis factor-alpha. Critical Care Medicine 25, 111-20.
40. Aderka, D., Le, J. M. & Vilcek, J. (1989). IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. Journal of Immunology 143, 3517-23.
41. Tilg, H., Dinarello, C. A. & Mier, J. W. (1997). IL-6 and APPs: antiinflammatory and immunosuppressive mediators. Immunology Today 18, 428-32.
42. Cenci, E., Mencacci, A., Casagrande, A. et al. (2001). Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. Journal of Infectious Diseases 184, 610-17.
43. Wang, H. & Tracey, K. J. (1999). Tumor necrosis factor, interleukin-6, macrophage migration inhibitory factor, and macrophage inflammatory protein-1 in inflammation. In Inflammation, Basic Principles and Clinical Correlates (Gallin, J. I. & Snyderman, R., Eds), pp. 471-86. Lippincott Williams and Wilkins, Philadelphia, PA, USA.
44. Schaffner, A., Douglas, H. & Braude, A. (1982). Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. Journal of Clinical Investigations 69, 617-31.
45. Cenci, E., Mencacci, A., Fe d'Ostiani, C. et al. (1998). Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. Journal of Infectious Diseases 178, 1750-60.
46. Romagnani, S. (1999). CD4 effector cells. In Inflammation, Basic Principles and Clinical Correlates (Gallin, J. I. & Snyderman, R., Eds), pp. 177-85. Lippincott Williams and Wilkins, Philadelphia, PA, USA.
47. Lechner, A. J., Tredway, T. L., Brink, D. S. et al. (1992). Differential systemic and intrapulmonary TNF-alpha production in Candida sepsis during immunosuppression. American Journal of Physiology 263, L526-35.
48. Schelenz, S., Smith, D. A. & Bancroft, G. J. (1999). Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-alpha and GM-CSF in neutrophil recruitment. Medical Mycology 37, 183-94.
49. Yamaguchi, H., Abe, S. & Tokuda, Y. (1993). Immunomodulating activity of antifungal drugs. Annals of the New York Acadamy of Sciences 685, 447-57.
50. Van Vlem, B., Vanholder, R., De Paepe, P. et al. (1996). Immunomodulating effects of antibiotics: literature review. Infection 24, 275-91.
51. Rogers, P. D., Jenkins, J. K., Chapman, S. W. et al. (1998). Amphotericin B activation of human genes encoding for cytokines. Journal of Infectious Diseases 178, 1726-33.
52. Rogers, P. D., Stiles, J. K., Chapman, S. W. et al. (2000). Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. Journal of Infectious Diseases 182, 1280-3.